TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s Phase I/II clinical study of oral psilocybin in the treatment of methamphetamine use…


Previous articleBexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™
Next articlePT356 – Brom Rector – Investing in Psychedelics and The Rush to Improve on the Classics